<unk>  (INN, codenamed PTK787 or PTK/ZK) is a small molecule protein kinase inhibitor that inhibits angiogenesis. It is being studied as a possible treatment for several types of cancer, particularly cancer that is at an advanced stage or has not responded to chemotherapy.<unk>  is orally active, that is, it is effective when taken by mouth.<unk>  is being developed by Bayer Schering and Novartis. It inhibits all known VEGF receptors, as well as platelet-derived growth factor receptor-beta and c-kit, but is most selective for VEGFR-2.
Vatalanib
Pegaptanib
Nintedanib
Tivozanib
Abrocitinib
Pazopanib
Alectinib
Gilteritinib